Cover Image

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective

BackgroundCost-effectiveness of atezolizumab, as a treatment for advanced non-small-cell lung cancer (NSCLC) patients who cannot receive a platinum-containing regimen,was still unknown. Our objective was to evaluate the cost-effectiveness of atezolizumab vs. chemotherapy in this indication from the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yunlin Jiang (Author), Mingye Zhao (Author), Jiayi Xi (Author), Jiaqi Li (Author), Wenxi Tang (Author), Xueping Zheng (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases
by: Yunlin Jiang, et al.
Published: (2024)

Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer
by: I. S. Krysanov, et al.
Published: (2023)

Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
by: Mingye Zhao, et al.
Published: (2023)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021)

Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents
by: Giannis Mountzios, et al.
Published: (2013)

GEMCITABINE / PLATINUM VS. VINORELBINE- PLATINUM IN PATIENTS WITH ADVANCED NON- SMALL- CELL LUNG CANCER
by: Deyan Davidov
Published: (2008)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
by: Phatcharawat Chirasuthat, et al.
Published: (2018)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Facchinetti F, et al.
Published: (2018)

Water Optics and Water Colour Remote Sensing
by: Yunlin Zhang (Ed.)
Published: (2017)

Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system
by: Gustavo Viani Arruda, et al.
Published: (2022)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
by: Qian-Yu Yang, et al.
Published: (2022)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
by: Mingye Zhao, et al.
Published: (2022)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
by: Matteo Franchi, et al.
Published: (2022)

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis
by: Xi Chen, et al.
Published: (2023)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
by: Miriam Alonso-García, et al.
Published: (2022)

Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy
by: Cheng Zhang, et al.
Published: (2022)

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
by: Yin-Ting Chuang, et al.
Published: (2012)

Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report
by: Davide Fattore, et al.
Published: (2024)

Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses
by: Song Ren, et al.
Published: (2023)

Nanocarriers containing platinum compounds for combination chemotherapy
by: Guihua Fang, et al.
Published: (2022)

Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy
by: Shao IH, et al.
Published: (2014)

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
by: Yao Z, et al.
Published: (2022)

Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia
by: Vukićević Đurđa, et al.
Published: (2020)

Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
by: Jelena Spasic, et al.
Published: (2022)

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
by: Pignata M, et al.
Published: (2017)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
by: Ida Netterberg, et al.
Published: (2020)

Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer
by: S. К. Zyryanov, et al.
Published: (2024)

The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials
by: Guangsu Han, et al.
Published: (2024)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022)

THERAPY FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WHO PRESENT LATE OR ARE INELIGIBLE FOR REPERFUSION
by: M. Cohen, et al.
Published: (2016)

A case of de novo psoriasis induced by atezolizumab in a patient with advanced lung cancer
by: Shigeruko Iijima, et al.
Published: (2019)

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients
by: Sophie Marolleau, et al.
Published: (2023)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
by: Lee Cheng Phua, et al.
Published: (2020)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2020)

Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer
by: Antonio Gonçalves, et al.
Published: (2024)

The Hemoglobin Level as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer Treated with Gemcitabine and cis-Platinum
by: Deyan N. Davidov
Published: (2012)